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Economic evaluations of clinical treatments most commonly take the form of cost eﬀectiveness or cost utility analyses. This is
appropriate since the main—sometimes the only—beneﬁt of such interventions is increased health. The majority of economic
evaluations in public health, however, have also been assessed using these techniques when arguably cost beneﬁt analyses would
in many cases have been more appropriate, given its ability to take account of nonhealth beneﬁts as well. An examination of the
nonhealth beneﬁts from a sample of studies featured in a recent review of economic evaluations in public health illustrates how
overfocusing on cost eﬀectiveness/cost utility analyses may lead to forgoing potential social welfare gains from programmes in
public health. Prior to evaluation, programmes should be considered in terms of the potential importance of nonhealth beneﬁts
and where these are considerable would be better evaluated by more inclusive economic evaluation techniques.
Copyright © 2009 D. R. Cohen and N. Patel. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Evidence-based medicine is now an established paradigm
within health care [1]. Growing recognition that resources
for health care are scarce has led to broad acceptance that
the evidence base should include economic as well as clinical
evidence. In the UK, this is reﬂected in the work of the
National Institute for Health and Clinical Excellence (NICE)
whose national guidance on health care for England and
Wales is explicitly informed by evidence of cost eﬀectiveness
as well as clinical eﬀectiveness [2].
The principal beneﬁts from most clinical treatments are
in the form of health gains to patients. While there can also
be nonhealth beneﬁts, for example, from earlier return to
work or in terms of reduced burden on informal carers ,
these tend to be relatively small. Since an objective of all
health care systems is to maximise the amount of health
produced (allowing for other objectives such as equity), it is
not surprising that the economic questions most commonly
addressed when evaluating clinical treatments are concerned
with identifying the most cost-eﬀective ways of producing
health.
There is now a growing movement toward incorporating
the principles of evidence-based medicine in evidence-based
public health. At the end of 2005, NICE announced that
it was extending its remit to include guidance on the
promotion of good health and the prevention of ill health [3]
thus explicitly recognising the contribution of public health
in improving health.
A review of economic evaluations in public health
was recently undertaken [4]. A total of 1697 papers met
the review’s inclusion criteria. Of these, 1235 (73%) were
classed as cost eﬀectiveness (CEA) or cost utility (CUA)
studies which assess how 68 cost eﬀectively a public health
programme produces health. Only 43 studies (2.5%) were
classed as cost beneﬁt analyses (CBA)—the technique of
economic evaluation which addresses the broader issue of
whether or not a public health programme is worthwhile.
This paper considers the fundamental diﬀerences
between CEA/CUA and CBA in the context of providing an
evidence base to inform public health policy. Using selected
studies from the database produced by the team that under-
took the review [4], this paper examines how information2 Journal of Environmental and Public Health
provided by CEA/CUA studies might lead to ineﬃcient
recommendations for public health policy. It does this by
brieﬂy reviewing the principles of the diﬀerent techniques of
economic evaluation, considers the fundamental diﬀerences
between public health and clinical treatments in terms of
their objectives, and then, on the basis of information from
a selection of studies, suggests a simple method for assessing
where CEA/CUA of public health programmes might make
a misleading contribution to the economic evidence base for
public health.
1.1. Principles of Economic Evaluation of Clinical Treatments.
Within health care, a cost eﬀectiveness analysis will assess
an intervention against a comparator in terms of cost per
unit of health eﬀect achieved. These units can be speciﬁc,
for example, true positive cases of presymptomatic disease
detected in a screening programme, or more generic, for
example, life years saved. In cost utility analysis, the unit
of eﬀectiveness is the Quality Adjusted Life Year (QALY) or
other single index measures which capture both life length
of life and quality of life. The technique’s name refers to
the fact that the quality of life element is determined by the
utilities, or values, attached to diﬀerent health states. Thus
while CUA outcomes take account of preferences they can
still be regarded as a form of CEA since they seek to ﬁnd
the least cost way of producing a health-related unit of eﬀect.
NICE determined early on that, where possible, CUA was the
preferred form of analysis to provide the economic evidence
for health care interventions [2].
CEA/CUA, however, only compare alternatives ways of
pursuing a single objective—in this case to maximise health
gain. An unambiguous result, however, is produced only if
the intervention in question is both more eﬀective and less
costly than the comparator (or vice versa). It is then said to
be “dominant” and there are no economic arguments for not
adopting it over the comparator.
A far more common result, however, is one of nondomi-
nance. This occurs where the intervention of interest is more
eﬀectivebutalsomorecostly.Whetherornotthehighercosts
are worth incurring, that is, whether additional resources
should be allocated to the treatment of these patients is an
allocative eﬃciency question which cannot be answered by
CEA/CUA.
In order to assist decision makers, nondominant results
are commonly presented in the form of incremental cost
eﬀectiveness ratios (ICERs) which show the extra cost
of achieving the extra health eﬀects. Cost eﬀectiveness
acceptability curves (CEACs) deal with the uncertainty
surrounding the estimates by showing the probability that a
nondominant intervention will have an ICER below a range
of thresholds which represent the maximum amounts that a
payer would be willing to pay for an extra unit of eﬀect [5].
Heuristics are often used to identify these thresholds. For
example, NICE currently regards an ICER of $30000 per
QALY as being at the upper limit for the interventions to be
recommended for use in the British National Health Service.
While the question of how much society is willing to pay
for extra health beneﬁts remains a live issue, the focus on
assessing the cost eﬀectiveness of clinical treatments through
CEA/CUA remains the norm.
Results of these analyses clearly depend on which costs,
including cost savings, are included, that is, on the perspec-
tive adopted. In the UK, NICE restricts the perspective to the
National Health Service and personal social services. Costs
(positive and negative) to other sectors are not considered—
at least in the primary analysis. This remains a contentious
issue as exempliﬁed in a recent NICE appraisal of drugs
for Alzheimer’s disease where a major issue was whether
or not to include cost borne by informal carers [6]a n da
recent editorial in the British Medical Journal has called for
a rethink on continued use of a narrow perspective even for
health service interventions [7].
1.2. Principles of Economic Evaluation in Public Health.
The UK Faculty of Public Health has adopted Sir Donald
Acheson’s deﬁnition of public health as “the science and art
of preventing disease, prolonging life and promoting health
throughorganisedeﬀortsofsociety”[8]. The Faculty regards
the key elements of public health as being population based,
emphasising collective responsibility for health, recognising
the key role of the state, and emphasising partnerships with
all those who contribute to the health of the population.
Theseprinciplesmakeitclearthatpublichealthprogrammes
can produce health in ways which do not necessarily involve
health professionals or involve the use of health services.
While these principles are captured in most deﬁnitions
of public health, the deﬁnition by Allin et al. ends with
“...and involves mobilising local, regional, national and
international resources to create conditions in which people
can be healthy” (emphasis ours) [9]. In contrast to producing
health by treating illness, creating the conditions in which
peoplecanbehealthywilloftenachieveimportantnonhealth
beneﬁts in addition to health. Evidence that such nonhealth
beneﬁts are positively valued was demonstrated in a study
by Cropper [10] which examined people’s preferences for
diﬀerent life saving programmes. When asked to choose
between programmes, a belief that a programme would
produce beneﬁts in addition to life saving was shown to
signiﬁcantly increase the probability of that programme
being preferred over another with the same life saving
beneﬁts.
Cost beneﬁt analysis (CBA) is the technique of economic
evaluation which addresses allocative eﬃciency. It explicitly
addresses the question “how much more or how much less
of society’s resources should be allocated to achieving this
goal or to this type of healthcare?” [11]. Its foundations are
rooted within welfare economics where the aim is to assess
how social welfare is aﬀected by a particular project [12].
CBA does this by identifying and measuring all costs and all
beneﬁts; deﬁned as everything of value that results (positive
or negative) and regardless of who gains or loses, that is,
using a societal perspective. When all gains and losses are
measured in commensurate terms (i.e., money) healthcare
objectives can be compared with each other or with those in
other sectors of the economy. If the total value of the beneﬁts
(gains) exceeds the total value of the costs (losses), then theJournal of Environmental and Public Health 3
proposal passes the cost beneﬁt test and total social welfare is
increased by implementing the programme.
AlthoughinprincipleCEA/CUAarecapableofcapturing
avoided costs in sectors other than health care, these analyses
would still not capture the full range of beneﬁts that would
be picked up in a CBA. For example, a CUA of a proposed
policy to reduce air pollution would be based on the narrow
premise that the objective of the policy is solely to produce
health. Thus, the beneﬁt side would include only health
gains.Iftheanalysisshowedanincrementalcost/QALYabove
a predetermined threshold, even if that analysis included
cost savings to sectors other than health such as reduced
cleaning costs due to reduced pollution, the implication
would be that resources should not be allocated to this
intervention. A CBA, however, which included nonhealth as
well as health beneﬁts—say the value attached to breathing
clean air independent of any health implications—might
show the same proposal to pass the cost beneﬁt test. In
this example, a policy decision taken on the basis of the
CUA would mean forgoing an opportunity to improve social
welfare.Itis,ofcourse,possiblethatnonhealthbeneﬁtscould
benegative whichreinforcestheimportance ofnot excluding
them, particularly where they are signiﬁcant.
Although economists have developed numerous meth-
odstoassignmoneyvaluestocostsandbeneﬁtswhichdonot
have associated market prices, this inevitably is not an easy
task which might explain why comprehensive CBAs remain
rare. It is well recognised that many studies which include
the word “cost beneﬁt analysis” in their title are, in reality,
not CBA studies at all [13]. Such mistitled studies frequently
use that term because they regard cost savings from avoided
future illness as ‘beneﬁts’ and thus feel that their analysis has
covered both sides of the cost beneﬁt calculus.
Someeconomicstudiesavoidvaluationproblemsbysim-
ply listing the costs and consequences of any activity without
aggregation. Such cost-consequences analyses (CCAs) are,
strictly, not economic evaluations as they cannot provide
answers to either cost eﬀectiveness or allocative eﬃciency
questions. However, by identifying costs and consequence
they can be an important aid to decision making beyond
cost eﬀectiveness ratios and a recent report from the Public
Health Research Consortium in the UK has called for
the intersectoral impacts of public health interventions to
be presented in the form of a cost-consequences analysis
[14].
In terms of an emerging public health evidence base,
there thus appears to be a problem. If the beneﬁts from
public health interventions frequently include more than
just health gains then, arguably, its evidence base ought
to include a smaller proportion of cost eﬀectiveness and
cost utility analyses than does the evidence base for clinical
treatments. Nevertheless, as shown in the review [4], nearly
three quarters of the economic evaluation undertaken in the
area of public health have to date been cost eﬀectiveness or
cost utility studies.
In ordertoillustratethe partialnatureoftheinformation
provided from CEA/CUA evaluations in public health, hence
the potential for ineﬃcient health policy, the present study
examined the nature and relative importance of beneﬁts
which were included in some of the economic studies which
went beyond cost eﬀectiveness or cost utility analyses in the
recent review [4].
2.MaterialsandMethods
Studies from the review were identiﬁed for possible selection
if they were not classed as cost eﬀectiveness or cost utility
studies. It was evident from examination of abstracts, how-
ever, that despite their classiﬁcation many of these studies
had limited their analyses to health beneﬁts alone. Omission
of nonhealth beneﬁts, even where they might be signiﬁcant,
is not necessarily a weakness in these studies. If the value of
the health beneﬁts alone can be shown to exceed the value of
all of the costs, then the intervention passes the cost beneﬁt
test without the need to consider any nonhealth beneﬁts.
Including them would only reinforce the conclusion already
reachedalthoughclearly,incompleteassessmentwouldmake
comparisons of the beneﬁt:cost ratios between programmes
problematic. Given the focus of the present exercise, these
studies were ignored.
Ten studies were selected for illustration (Table 1). Of
these two had been classed within the review as CBA; the
remainder being CCA or multimethod apart from one case
where no classiﬁcation was given.
3. Results
The work by Aunan et al. [15] evaluated the costs and
beneﬁtsofimplementingtoreduceairpollutionprogramme.
Reduced damage to public health, building materials, and
agricultural crops from reduced emissions of air pollutants
was assessed over two medium term targets (5 years
and 10 years). The possible beneﬁts from implementing
the measures described by the National Energy Eﬃciency
Improvement and Energy Conservation Program were eval-
uated using saved energy from various sectors: households,
transportation, industry, service, energy, and agriculture.
Health beneﬁts included those from acute respiratory
symptoms, chronic respiratory symptoms, infant deaths,
and lung cancer. Nonhealth beneﬁts included damage to
materials through atmospheric corrosion and deterioration
ofmaterials.Thisincludedthemaintenanceandreplacement
costs from reducing SO2 concentration levels. Crop loss due
to SO2 w a ss e e nt ob eag r e a tc o n c e r nf o rc r o pp r o d u c t i o n .
The analysis indicated that the annual beneﬁt of
improved health alone is likely to exceed the investment
needed to implement the programme. Thus, the policy
would pass the cost beneﬁt even without inclusion of the
signiﬁcant beneﬁts due to reduced damage to materials and
crops.
The work by Miller et al. [16] modelled the potential
health and economic impacts of implementing a medically
prescribed heroin programme among Canadian injecting
drug users over 5 years. The potential impact of the
programme was estimated by comparing hospitalisation and
emergency use costs. Nonhealth costs in the study included
criminal activity and productivity losses.4 Journal of Environmental and Public Health
Table 1: Selected studies from review [4] database.
Author Year Title Country of
study Area of Study Evaluation
method
Nonhealth beneﬁts
measured
Aunan et al. [15] 1998
Health and environmental
beneﬁtsfrom air pollution
reductions in Hungary
Hungary Pollution / Toxicity CCA
Avoided damage to
materials, crops and
vegetation; climate
change
Caulkins et al. [17] 1999
An ounce of prevention, a
pound of uncertainty:The
cost-eﬀectiveness
school-based drug
prevention programs
USA Drugs and alcohol Multitype
Reduced crime rates;
higher productivity;
increase in numbers
graduating high school
Cohen MA et al. [18] 1998 The monetary value of
saving a high-risk youth USA Health Promotion Not classiﬁed
Reduced victim costs of
crime; savings to
criminal justice system
Fleming et al. [19] 2000
Beneﬁt-cost analysis of
briefphysician advice with
problem drinkers in
primary settings
USA Drugs and alcohol CCA
Savings in lost wages,
transportation, legal
events, motor vehicle
accidents and crime
Guria et al. [20] 1998
An economic evaluation of
incremental resources to
road safety programmes in
New Zealand
New Zealand Drugs/ Alcohol CBA Reduced property
damage
Aehyung et al. [21] 1995
Cost Beneﬁt Analysis of
theOnchocerciasis
Program
Africa Disease and
Infection CCA
Additional agricultural
output and freed land
for productivity
Miller C.L et al. [16] 2004
The potential health and
economicimpact of
implementing a
medicallyprescribed heroin
program among Canadian
injection drug users
Canada Drugs and Alcohol Multi type
Increased employment,
reduction in criminal
activity
Miller T.R et al. [22] 1995
Injury Prevention
Counselling by
Paediatricians: A Beneﬁt-
Cost Comparison.
USA Health Promotion CBA
Savings from
professional services,
rehabilitation, avoided
productivity losses
Zeng-Sui et al. [23] 1989
Reduction of enteric
infectiousdisease in rural
China by providing
deep-well water
China Disease and
Infection CCA Lost wages,
Ginsberg et al. [24] 1994
A cost- beneﬁt analysis of
legislation for bicycle safety
helmets in Israel
Israel Injury Prevention CBA
Increased productivity,
savings in special
education
Beneﬁts were measured by the reduction in these costs.
Reductions in criminal activity costs accounted for fully 63%
of the total reduction in costs. Other costs avoided since the
implementation of the programme such as the costs of social
housing, use of social services, counseling, and employment
programs were identiﬁed but not included in the model.
Although this study did not claim to be a CBA it provides
an example of an intervention whose nonhealth beneﬁts
were signiﬁcantly larger than the health beneﬁts. Had the
researchers attempted a CBA, the nonhealth beneﬁts could
have made the diﬀerence between the programme passing or
failing the cost beneﬁt test.
T h ew o r kb yZ e n g - S u ie ta l .[ 23] assessed the impact on
enteric infectious disease by providing deep-well tap water
across six villages in China. Health beneﬁts included reduc-
tions in diarrhoea, dysentery, viral hepatitis, cholera, and
reduce mortality form liver cell cancer. Nonhealth beneﬁts
included reductions in lost wages or earnings of patients and
oftheirrelativeswholookedafterthemduringtheillnessand
the avoided costs of transportation, supplemental nutrition,
and the value of gifts sent by relatives to assist towards their
recuperation (but interestingly not the value of the gift to
the recipient which illustrates how the gifts should have been
regarded as a ﬁnancial transfer [25] rather than an economic
cost avoided).
The study did not include all health beneﬁts. For
example, water-related conditions such as skin and eye
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enteric diseases, and vector-borne diseases were mentioned
but not included. Other intangible beneﬁts such as the
improved service that will beneﬁt future generations were
also mentioned but not included in the analysis. Overall
assessed beneﬁts were more than double the costs.
The work by Guria et al. [20] evaluated the incremental
outcomes of road safety programmes and driving campaigns
enforced in New Zealand and compared them with their
resource costs. In addition to loss of life and reduced
quality of life resulting from injury, the study also included
the social costs of injuries and property damage avoided.
Other beneﬁts such as the development of a safety culture,
improvement of road user behaviour, and the safety quality
of vehicles were mentioned but not included.
The study showed that road safety programmes aimed
at reducing high-risk behaviours produced high returns. If
90% of road safety expenditure is attributed to the period of
investment, then the beneﬁt to cost ratio would be 12.3 : 1
for 1993–1995 and 7.9 : 1 for 1994–1996.
The work by Aehyung et al. [21] presented a CBA of the
onchocerciasis (river blindness) control programme. Health
beneﬁts included the number of cases of blindness and death
prevented. Nonhealth beneﬁts included additional agricul-
tural output as a result of a more productive labour force
and additional agricultural land made available through
the control of onchocerciasis. Other nonhealth beneﬁts
such as the reduction of lost production time by family
members when providing care and improved parenting were
mentioned but not included in the study.
The study showed that the land related beneﬁts were
large. The net present value (NPV) ranged from US$485
million to US$3,792 million (1987 dollars) depending on the
assumptions used. A positive NPV is another way of saying
that the programme passed the cost beneﬁt test.
The work by Fleming et al. [19] estimated the costs
and beneﬁts of brief physician advice with problem drinkers
in primary care settings. Health care beneﬁts included
avoided cost from the perspective of the managed care
organisation, the use of equipment, personnel, emergency
medical care, hospitalisations, treatments, and clinic visits.
Nonhealth beneﬁts included legal events and motor vehicle
accidents.
The study indicated that physician-delivered advice can
reduce not only medical costs but also social costs associated
with alcohol consumption. The total economic cost of the
intervention was $80,210, or $205 (1993 dollars) per study
patient. The total beneﬁt of this brief physician intervention
was $423,519. The total beneﬁt was equal to $1,151 per study
patient.
The study by Cohen et al. [18] estimated the potential
beneﬁts from saving a “high-risk youth” by estimating the
lifetime costs associated with the career criminal drug abuser
and high school drop out. Antisocial behaviour of career
criminals was included as an externality and thus seen
as imposing as a social cost. Assessed nonhealth beneﬁts
included the avoided social costs from stolen property and
lost wages.
As this study did not examine the costs of interventions
aimed at reducing antisocial behaviour, it was not a CBA.
However, the range and magnitude of the nonhealth beneﬁts
whichwereincluded in the valuation exercise illustrateswhat
would be missed if a CEA/CUA study focussing solely on the
health beneﬁts had been undertaken.
The work by Caulkins et al. [17] on school-based
drug prevention programmes focused on reducing drug
consumption, particularly cocaine, as an objective of the
nation’sdrugcontroleﬀorts.Thestudyreportedthequantity
of cocaine consumed, the cost of drug use, and the social
value of cocaine control.
Beneﬁts from the prevention program included reduc-
tions in the use of other drugs including marijuana,
alcohol, and cigarettes. Nonhealth beneﬁts included lower
crime rates, higher productivity, and an increase in the
number of pupils graduating from high school graduation.
The programme was deemed to be aﬀordable and social
beneﬁts were shown to exceed the total costs which justiﬁed
implementation of the programme.
The work Ginsberg et al. [24] estimated the costs of
making the wearing of bicycle helmets compulsory in Israel.
Beneﬁts included resource saving from fewer head injuries in
terms of hospitalisation, emergency room visits, ambulatory
care, rehabilitation, long-term care, and special education.
Also included were productivity beneﬁts and the value of
avoided death.
The authors called their analysis “conservative” as “...it
did not consider reduced pain, worry, grief, work losses for
ambulatory visits or even time oﬀ from housework as a
result of bicycle injuries. Nor did we consider the intangible
beneﬁts of the lessening of anxiety concerning crashes by
cyclists or by their friends and relatives.”
Inclusion of these additional beneﬁts was unnecessary as
thepartialbeneﬁts(total =US$60.7million)clearlyexceeded
total costs (US$20.1 million) without their inclusion (dollar
base year not stated). In this example, the health service
savings alone (US$44.2 million) were suﬃcient for the
proposed policy to pass the cost beneﬁt test. If, however,
the results showed that the productivity gains (US$7.5
million) were needed to tip the balance, then their omission
would have meant a lost opportunity to increase social
welfare.
The work by Miller et al. [22] examined counselling by
paediatricians aimed at reducing injuries in children. Bene-
ﬁts included savings from hospital admissions, professional
services, rehabilitation, prescriptions, home health care, and
medical equipment. The study also included beneﬁts from
avoided productivity losses due to children not being able
to work when they became adults if they were killed or
permanently disabled and included a value for avoided pain,
grief, and suﬀering.
The study was acknowledged to be only partial. For
example, it mentioned but did not include productivity
losses from parents dealing with injured children. Never-
theless, it still showed a beneﬁt to cost ratio of nearly
13 : 1. In this case, however, annual productivity beneﬁts
($660 million) were nearly 3 times those of health service
beneﬁts ($230 million) (1992 dollars) which in a higher-cost
programme might have made the diﬀerence between passing
or failing the cost beneﬁt test.6 Journal of Environmental and Public Health
4. Discussion
It is evident that many public health interventions produce
beneﬁts in addition to health and in many cases these can be
substantial. Some of these involve resource savings which, if
regarded as negative costs could in principle be included in a
CEA/CUE provided that a societal perspective were adopted.
Others,however,forexample,reductionsincriminalactivity,
are clearly of value independent of any cost savings and
these would not feature in a cost eﬀectiveness or cost utility
study.
The extent to which the noninclusion of nonhealth
beneﬁts in evaluation by CEA/CUA represents a problem—
in the sense that it could potentially lead to foregone
opportunities to increase social welfare—might be predicted
by considering where the intervention in question would sit
along a continuum of intent.
At one extreme of such a continuum would be public
health measures whose intent was solely to produce health.
For example, a policy to add folic acid to ﬂour has been
advocated with the speciﬁc intent of reducing the incidence
of neural tube defects (NTD) in newborns [26]. Where
health gains are the sole objective of a public health
programme then, on the same principles used within health
care, they can be assessed in terms of cost eﬀectiveness. If
the addition of folic acid to ﬂour were shown to have a
low incremental cost/QALY, then this public health measure
would be a cost-eﬀective way of producing health relative to
interventions within health care.
Even in this example, however, there could still be a case
for directly addressing allocative eﬃciency through CBA, for
example, if women of childbearing age receive immediate
reassurance from the knowledge that eating fortiﬁed food
reduces their risk of conceiving a baby with an NTD. Equally,
making consumption of folic acid compulsory removes
freedomofchoicewhichtomanycouldbeahighlynegatively
valued nonhealth outcome.
Moreover, although there are no rules within the
methodologyofeconomicevaluationtopreventaCUAbeing
undertaken from a broad perspective—-and there have been
recent calls to do just that [7]—such evaluations remain
uncommon.Inthefolicacidexample,thecost/QALYderived
from a study which adopted a health service perspective
would not include savings to other agencies such as special
education which in the case of children with NTD could be
substantial.
Further along the continuum of intent would be public
health interventions where health is the primary concern but
other objectives will clearly also be achieved. Thus, while
a road safety intervention may be advocated primarily to
reduce injury and death on the roads, it is evident that a
reduction in accidents will also produce savings in terms of
property damage. The study by Guria et al. [20]o nr o a d
safety in New Zealand included property damage in deriving
i t sc o s tb e n e ﬁ tr a t i o s .
Further still along the continuum would be public health
interventions which clearly address multiple objectives. For
example,illegaldruguseisknowntocausemanysocialprob-
lems as well as health problems. Thus the study by Caulkins
et al. [17] included reduced crime and increased produc-
tivity among the beneﬁts of schools-based drug prevention
programmes, even taking account of intangible beneﬁts such
as an increase in the proportion of pupils graduating from
high school. Another example is the onchocerciasis preven-
tion programme examined by Aehyung et al. [21] which,
although driven by a desire to reduce the incidence of river
blindness, would also free previously oncho-ridden tracts
of land for settlement and cultivation. In both these exam-
ples, CUAs would have given misleading information for
policy.
Further still along the continuum would be programmes
which could be perceived as being only incidentally pre-
ventive in the sense that the eﬀect of pursuing another
policy objective would incidentally have a positive eﬀect
on health. An example here could be improvements in
housing which are undertaken to provide people with more
pleasant places to live but which can at the same time aﬀect
respiratory illnesses or reduce injuries. The health eﬀects
of such programme can be assessed via a “health impact
assessment.’’
Ultimately almost any public policy can be seen as
containing an element of public health. For example,
macroeconomic policies to stimulate economic growth are
clearly driven by concerns other than health, yet eco-
nomic growth reduces unemployment and the relationship
between unemployment and ill health is long established
[27].
5. Conclusion
Public health programmes can have nonhealth beneﬁts
which may not be captured when a cost eﬀectiveness/cost
utility approach to economic evaluation is undertaken.
Omission of nonhealth beneﬁts could mean forgoing oppor-
tunities to improve social welfare. A preanalysis examination
of where any public health intervention would be located
on a continuum of intent (relative importance of health
versus nonhealth beneﬁts) could identify where evaluation
by cost eﬀectiveness or cost utility analysis might produce
inappropriate conclusions for policy.
Many of the public health programmes which to date
havebeenassessedbyCEA/CUA,inparticular,thoseaddress-
ing smoking cessation [28] have shown incremental cost
eﬀectiveness ratios which are far below current thresholds.
In such cases, the use of more comprehensive techniques is
unnecessary. Equally, where a CBA is undertaken and the
value of the health beneﬁts alone is anticipated to clearly
outweigh the costs, addition of nonhealth beneﬁts will not
aﬀect the decision on whether to implement the programme
and hence their inclusion is again unnecessary. Most public
health programmes, however, are unlikely to allow such
o b v i o u sap r i o r ic o n c l u s i o n st ob ed r a w na n di ti sh e r e
that consideration of where the programme sits along the
suggested continuum of intent will increase the likelihood
that the most appropriate technique of economic evaluation
will be used.Journal of Environmental and Public Health 7
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